New allergy vaccine could end spring sniffles

NCT ID NCT07155499

Ongoing Symptom relief Sponsor: AO GENERIUM Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new treatment called GNR-127 for people with seasonal allergies to birch pollen. The treatment is a protein that aims to reduce allergy symptoms like sneezing, runny nose, and itchy eyes. The trial involves 150 adults and will check for safety and how well it works compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNR-127 (a recombinant birch pollen allergen protein)
What this could lead to: If it works, this could lead to a treatment that reduces or eliminates allergy symptoms like sneezing and itchy eyes during birch pollen season.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet proven. The results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease allergic rhinitis immune system disorder Respiratory Hypersensitivity respiratory system disorder seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHINITIS, ALLERGIC, SEASONAL

Contacts and locations

Locations

National Research Center - Institute of Immunology Federal Medical-Biological Agency

Moscow, 115522, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.